Palladium-103 (103Pd/103mRh), a promising Auger-electron emitter for targeted radionuclide therapy of disseminated tumor cells - absorbed doses in single cells and clusters, with comparison to 177Lu and 161Tb
Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emissi...
Uložené v:
| Vydané v: | Theranostics Ročník 14; číslo 11; s. 4318 - 4330 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Sydney
Ivyspring International Publisher
01.01.2024
|
| Predmet: | |
| ISSN: | 1838-7640, 1838-7640 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emission of Auger and conversion electrons. Methods: The Monte Carlo track structure code CELLDOSE was used to assess absorbed doses in single cells (14-μm diameter; 10-μm nucleus) and clusters of 19 cells. The radionuclide was distributed on the cell surface, within the cytoplasm, or in the nucleus. Absorbed doses from 103Pd, 177Lu and 161Tb were compared after energy normalization. The impact of non-uniform cell targeting, and the potential benefit from dual-targeting was investigated. Additional results related to 103mRh, if used directly, are provided. Results: In the single cell, and depending on radionuclide distribution, 103Pd delivered 7- to 10-fold higher nuclear absorbed dose and 9- to 25-fold higher membrane dose than 177Lu. In the 19-cell clusters, 103Pd absorbed doses also largely exceeded 177Lu. In both situations, 161Tb stood in-between 103Pd and 177Lu. Non-uniform targeting, considering four unlabeled cells within the cluster, resulted in moderate-to-severe dose heterogeneity. For example, with intranuclear 103Pd, unlabeled cells received only 14% of the expected nuclear dose. Targeting with two 103Pd-labeled radiopharmaceuticals minimized dose heterogeneity. Conclusion: 103Pd, a next-generation Auger emitter, can deliver substantially higher absorbed doses than 177Lu to single tumor cells and cell clusters. This may open new horizons for the use of TRT in adjuvant or neoadjuvant settings, or for targeting minimal residual disease.Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emission of Auger and conversion electrons. Methods: The Monte Carlo track structure code CELLDOSE was used to assess absorbed doses in single cells (14-μm diameter; 10-μm nucleus) and clusters of 19 cells. The radionuclide was distributed on the cell surface, within the cytoplasm, or in the nucleus. Absorbed doses from 103Pd, 177Lu and 161Tb were compared after energy normalization. The impact of non-uniform cell targeting, and the potential benefit from dual-targeting was investigated. Additional results related to 103mRh, if used directly, are provided. Results: In the single cell, and depending on radionuclide distribution, 103Pd delivered 7- to 10-fold higher nuclear absorbed dose and 9- to 25-fold higher membrane dose than 177Lu. In the 19-cell clusters, 103Pd absorbed doses also largely exceeded 177Lu. In both situations, 161Tb stood in-between 103Pd and 177Lu. Non-uniform targeting, considering four unlabeled cells within the cluster, resulted in moderate-to-severe dose heterogeneity. For example, with intranuclear 103Pd, unlabeled cells received only 14% of the expected nuclear dose. Targeting with two 103Pd-labeled radiopharmaceuticals minimized dose heterogeneity. Conclusion: 103Pd, a next-generation Auger emitter, can deliver substantially higher absorbed doses than 177Lu to single tumor cells and cell clusters. This may open new horizons for the use of TRT in adjuvant or neoadjuvant settings, or for targeting minimal residual disease. |
|---|---|
| AbstractList | Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emission of Auger and conversion electrons. Methods: The Monte Carlo track structure code CELLDOSE was used to assess absorbed doses in single cells (14-μm diameter; 10-μm nucleus) and clusters of 19 cells. The radionuclide was distributed on the cell surface, within the cytoplasm, or in the nucleus. Absorbed doses from 103Pd, 177Lu and 161Tb were compared after energy normalization. The impact of non-uniform cell targeting, and the potential benefit from dual-targeting was investigated. Additional results related to 103mRh, if used directly, are provided. Results: In the single cell, and depending on radionuclide distribution, 103Pd delivered 7- to 10-fold higher nuclear absorbed dose and 9- to 25-fold higher membrane dose than 177Lu. In the 19-cell clusters, 103Pd absorbed doses also largely exceeded 177Lu. In both situations, 161Tb stood in-between 103Pd and 177Lu. Non-uniform targeting, considering four unlabeled cells within the cluster, resulted in moderate-to-severe dose heterogeneity. For example, with intranuclear 103Pd, unlabeled cells received only 14% of the expected nuclear dose. Targeting with two 103Pd-labeled radiopharmaceuticals minimized dose heterogeneity. Conclusion: 103Pd, a next-generation Auger emitter, can deliver substantially higher absorbed doses than 177Lu to single tumor cells and cell clusters. This may open new horizons for the use of TRT in adjuvant or neoadjuvant settings, or for targeting minimal residual disease.Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emission of Auger and conversion electrons. Methods: The Monte Carlo track structure code CELLDOSE was used to assess absorbed doses in single cells (14-μm diameter; 10-μm nucleus) and clusters of 19 cells. The radionuclide was distributed on the cell surface, within the cytoplasm, or in the nucleus. Absorbed doses from 103Pd, 177Lu and 161Tb were compared after energy normalization. The impact of non-uniform cell targeting, and the potential benefit from dual-targeting was investigated. Additional results related to 103mRh, if used directly, are provided. Results: In the single cell, and depending on radionuclide distribution, 103Pd delivered 7- to 10-fold higher nuclear absorbed dose and 9- to 25-fold higher membrane dose than 177Lu. In the 19-cell clusters, 103Pd absorbed doses also largely exceeded 177Lu. In both situations, 161Tb stood in-between 103Pd and 177Lu. Non-uniform targeting, considering four unlabeled cells within the cluster, resulted in moderate-to-severe dose heterogeneity. For example, with intranuclear 103Pd, unlabeled cells received only 14% of the expected nuclear dose. Targeting with two 103Pd-labeled radiopharmaceuticals minimized dose heterogeneity. Conclusion: 103Pd, a next-generation Auger emitter, can deliver substantially higher absorbed doses than 177Lu to single tumor cells and cell clusters. This may open new horizons for the use of TRT in adjuvant or neoadjuvant settings, or for targeting minimal residual disease. Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emission of Auger and conversion electrons. Methods: The Monte Carlo track structure code CELLDOSE was used to assess absorbed doses in single cells (14-μm diameter; 10-μm nucleus) and clusters of 19 cells. The radionuclide was distributed on the cell surface, within the cytoplasm, or in the nucleus. Absorbed doses from 103Pd, 177Lu and 161Tb were compared after energy normalization. The impact of non-uniform cell targeting, and the potential benefit from dual-targeting was investigated. Additional results related to 103mRh, if used directly, are provided. Results: In the single cell, and depending on radionuclide distribution, 103Pd delivered 7- to 10-fold higher nuclear absorbed dose and 9- to 25-fold higher membrane dose than 177Lu. In the 19-cell clusters, 103Pd absorbed doses also largely exceeded 177Lu. In both situations, 161Tb stood in-between 103Pd and 177Lu. Non-uniform targeting, considering four unlabeled cells within the cluster, resulted in moderate-to-severe dose heterogeneity. For example, with intranuclear 103Pd, unlabeled cells received only 14% of the expected nuclear dose. Targeting with two 103Pd-labeled radiopharmaceuticals minimized dose heterogeneity. Conclusion: 103Pd, a next-generation Auger emitter, can deliver substantially higher absorbed doses than 177Lu to single tumor cells and cell clusters. This may open new horizons for the use of TRT in adjuvant or neoadjuvant settings, or for targeting minimal residual disease. |
| Author | Champion, Christophe Hindié, Elif Larouze, Alexandre Alcocer-Ávila, Mario Morgat, Clément |
| AuthorAffiliation | 1 Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, F-33400, Talence, France 2 Institut Universitaire de France, 1 rue Descartes, 75231 Paris cedex 05, France 3 Université de Bordeaux-CNRS-CEA, Centre Lasers Intenses et Applications, UMR 5107, 33405 Talence, France |
| AuthorAffiliation_xml | – name: 2 Institut Universitaire de France, 1 rue Descartes, 75231 Paris cedex 05, France – name: 1 Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, F-33400, Talence, France – name: 3 Université de Bordeaux-CNRS-CEA, Centre Lasers Intenses et Applications, UMR 5107, 33405 Talence, France |
| Author_xml | – sequence: 1 givenname: Elif surname: Hindié fullname: Hindié, Elif – sequence: 2 givenname: Alexandre surname: Larouze fullname: Larouze, Alexandre – sequence: 3 givenname: Mario surname: Alcocer-Ávila fullname: Alcocer-Ávila, Mario – sequence: 4 givenname: Clément surname: Morgat fullname: Morgat, Clément – sequence: 5 givenname: Christophe surname: Champion fullname: Champion, Christophe |
| BookMark | eNpVUMtq3TAQNSWBpmk2-YJZphAnGr9kr0oIfcGFhpCsjR7jaxVZciW5JX_ZT6puexftLGaGmXPOPN4UJ847KopLZDccW3abZudvhrapu1fFGfZ1X_KuYSf_5K-Lixi_sWwNqwYczopfD8Jaoc22lMhquMruQd9mvzzO765BwBr8YqJxe7jb9hRKsqRS8A5oMSlRgMkHSCLsKZGGkKW825Q1miDNFMT6An4CbWLMBCcOoLQtmaPI2gglCBl9kLmsfaQIxsFhmqUjQDgNym4xj4rX8NOkGZRfVhFMzEskD8j5bvsDww6f5NvidBI20sUxnhfPHz883X8ud18_fbm_25VrhSyVyDV2k56aAZVUOTLFlJC8xUZU1FW9xAoHVTEmmrZXQ498aroJleKyYVLW58X7v7rrJhfSilwKwo5rMIsIL6MXZvy_48w87v2PEbFmNeM8K1wdFYL_vlFMY3704WjhyG9xrNnAurod-qb-DdLdmLM |
| ContentType | Journal Article |
| Copyright | The author(s). The author(s) 2024 |
| Copyright_xml | – notice: The author(s). – notice: The author(s) 2024 |
| DBID | 7X8 5PM |
| DOI | 10.7150/thno.95436 |
| DatabaseName | MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1838-7640 |
| EndPage | 4330 |
| ExternalDocumentID | PMC11303077 |
| GroupedDBID | --- 53G 5VS 7X7 7X8 8FI 8FJ ABUWG ADBBV AENEX AFKRA ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU DIK FYUFA GROUPED_DOAJ HMCUK KQ8 M48 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PUEGO RPM UKHRP 5PM AFFHD |
| ID | FETCH-LOGICAL-p210t-17d16fdf491cbcdf40c0cab7514a2e628b1219c200a458c9817f46f1cc7b40bb3 |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001313231700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1838-7640 |
| IngestDate | Tue Nov 04 02:06:20 EST 2025 Fri Sep 05 11:29:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-p210t-17d16fdf491cbcdf40c0cab7514a2e628b1219c200a458c9817f46f1cc7b40bb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have declared that no competing interest exists. |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11303077 |
| PQID | 3090635984 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11303077 proquest_miscellaneous_3090635984 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Sydney |
| PublicationPlace_xml | – name: Sydney |
| PublicationTitle | Theranostics |
| PublicationYear | 2024 |
| Publisher | Ivyspring International Publisher |
| Publisher_xml | – name: Ivyspring International Publisher |
| SSID | ssj0000402919 |
| Score | 2.384452 |
| Snippet | Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is... |
| SourceID | pubmedcentral proquest |
| SourceType | Open Access Repository Aggregation Database |
| StartPage | 4318 |
| SubjectTerms | Research Paper |
| Title | Palladium-103 (103Pd/103mRh), a promising Auger-electron emitter for targeted radionuclide therapy of disseminated tumor cells - absorbed doses in single cells and clusters, with comparison to 177Lu and 161Tb |
| URI | https://www.proquest.com/docview/3090635984 https://pubmed.ncbi.nlm.nih.gov/PMC11303077 |
| Volume | 14 |
| WOSCitedRecordID | wos001313231700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1838-7640 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402919 issn: 1838-7640 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1838-7640 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402919 issn: 1838-7640 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1838-7640 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402919 issn: 1838-7640 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1838-7640 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402919 issn: 1838-7640 databaseCode: PIMPY dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLf2wQEOiE8xGNND4gDqwuLGre3jmIZAYlM0FWmcKieOWaQsmdqmGhz4G_mTeLaTNO0JkLikrWs7bd7Pfs_Pv_dMyGsRam40DkBjtApYNooClWYjxDJWp6EZc6ndYRP8_FxcXsp4a3u_jYVZFrwsxe2tvPmvosYyFLYNnf0LcXedYgG-R6HjFcWO1z8SfGxd4zqv7dwXuTxMYRRrt3SOri-ucOnvGJuWmYUydl6R2nr22gNxBtl1bkN8PAHREcXRKJ1hl1VZp0Wus4EP2nJ7824_39JpbKVFfY1t7F7AfBAMVDKvZgkW62ruaF8De7ciayq4gLqitokaHJYaEnx3LCIaxZTzz7WriBbjJOkb0hP7E8rKZZleuc9Lnfud_4axZjq-kZpV9Y-sF9KzIv0eF6gU8AHYloIu80I1QUyeotZQkr8pT5Ap_A06wlDjMRmyDY_Jp-V3v-e94XTt4hC8avT6QKA-4GOfUapTGKw_MGhv-kdrTPRMCRb5PadNNcXRCkexL67K6p0csWgjF7izLuKzE2rti5DzbbI75CNp5-yznysPIk6_Q0mlz7lruzxadbi2Xlpn-_bMp8kDcr9Z98Cxx-tDspWVj8i9XjbMx-TXGnLhjcPtkUft20NQ0CEW1hELDWIBEQstYqGPWGgQC5WBPmLBIRYcICGAFrHgEAt5CR6xTQVEDbSIPQSLV1jhFRYVOLy6ag6vT8iXD6eTk49Bc-BIcDOk4SKgXNOx0YZJmiYpvoZpmKqE46JCDbPxUCQUFXyKs41iI5FKQblhY0PTlCcsTJLoKdkpqzJ7RiDVOgoVFwYFx1RIE8aMkWOdSBMqQbM98qoV0BQfnf0bqsyqej6NQonLhpEUbI-INclNb3wCmqlNCb_-TZlfudTwLWSe_3vTF-TuatDsk53FrM5ekjvpcpHPZwdkm19ydxUHZPf96Xl8ceBgiZ_iT2fx198PLu6i |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Palladium-103+%28103Pd%2F103mRh%29%2C+a+promising+Auger-electron+emitter+for+targeted+radionuclide+therapy+of+disseminated+tumor+cells+-+absorbed+doses+in+single+cells+and+clusters%2C+with+comparison+to+177Lu+and+161Tb&rft.jtitle=Theranostics&rft.au=Hindi%C3%A9%2C+Elif&rft.au=Larouze%2C+Alexandre&rft.au=Alcocer-%C3%81vila%2C+Mario&rft.au=Morgat%2C+Cl%C3%A9ment&rft.date=2024-01-01&rft.pub=Ivyspring+International+Publisher&rft.eissn=1838-7640&rft.volume=14&rft.issue=11&rft.spage=4318&rft.epage=4330&rft_id=info:doi/10.7150%2Fthno.95436&rft.externalDocID=PMC11303077 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1838-7640&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1838-7640&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1838-7640&client=summon |